Fig. 1: Beraprost treatment prevents bone loss induced by ovariectomy.
From: Beraprost ameliorates postmenopausal osteoporosis by regulating Nedd4-induced Runx2 ubiquitination
A Representative images of micro-CT reconstruction of distal femurs. B–F Quantitative analyses of micro-CT of distal femurs. Results are shown as mean ± standard deviation (SD); n = 5; *P < 0.05, **P < 0.01, and ***P < 0.001 by analysis of variance (ANOVA) with Tukey’s post-hoc test. BMD bone mineral density (mg/cm3); Tb.N trabecular number (1/µm), Tb.Sp trabecular separation (µm), Tb.Th trabecular thickness (µm), BV/TV bone volume (%). G, H Serum concentration of β-CTX and P1NP. Results are shown as mean ± SD; n = 5; **P < 0.01, ***P < 0.001 by ANOVA with Tukey’s post-hoc test. I Representative images of calcein double-labeled distal femurs. Scale bars = 50 μm. J, K Quantification of mineral apposition rate (MAR, µm/day), and bone-formation rate over bone surface (BFR/BS, µm3/µm2/day). Results are shown as mean ± SD; n = 5; ***P < 0.001 by ANOVA with Tukey’s post-hoc test. L Concentrations of β-CTX, P1NP, osteocalcin, and 1,25-dihydroxvitamin in serum of postmenopausal women. Results are shown as mean ± SD; n = 26, *P < 0.05, **P < 0.01 by t test.
